

In a further aspect of the present disclosure, there is provided a method of inducing non-therapeutic weight-loss in a subject, comprising administration of an effective amount of a compound as described herein, or a pharmaceutically acceptable salt thereof.

5 In another aspect of the present disclosure, there is provided a compound as described herein, or a pharmaceutically acceptable salt thereof, for use in therapy.

In yet another aspect of the present disclosure, there is provided a compound as described herein, or a pharmaceutically acceptable salt thereof, for use in the treatment of type 2 diabetes.

10 In a further aspect of the present disclosure, there is provided a compound as described herein, or a pharmaceutically acceptable salt thereof, for use in the treatment of obesity.

In another aspect of the present disclosure, there is provided a compound as described herein, or a pharmaceutically acceptable salt thereof, for use in the treatment of
15 nonalcoholic fatty liver disease (NAFLD).

In yet another aspect of the present disclosure, there is provided a compound as described herein, or a pharmaceutically acceptable salt thereof, for use in the treatment of nonalcoholic steatohepatitis (NASH).

20 In a further aspect of the present disclosure, there is provided an intermediate compound of the following formula:

His-Xaa2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-
Lys-Lys-Ala-Lys-Glu-Phe-Val-Glu-Trp-Leu-Leu-Xaa28-Gly-Gly-Pro-Ser-
Ser-Gly

wherein

25 Xaa2 is Aib;

Xaa28 is Glu or Ser; and

the C-terminal amino acid is optionally amidated (SEQ ID NO: 9),

or a pharmaceutically acceptable salt thereof.

30 In another aspect of the present disclosure, there is provided a process for the manufacture of a compound of the following formula:

16. A method of inducing non-therapeutic weight-loss in a subject, comprising administration of an effective amount of a compound according to any one of Claims 1 to 10, or a pharmaceutically acceptable salt thereof.
- 5 17. A compound according to any one of Claims 1 to 10, or a pharmaceutically acceptable salt thereof, for use in therapy.
18. A compound according to any one of Claims 1 to 10, or a pharmaceutically acceptable salt thereof, for use in the treatment of type 2 diabetes.
19. A compound according to any one of Claims 1 to 10, or a pharmaceutically acceptable salt thereof, for use in the treatment of obesity.
- 10 20. A compound according to any one of Claims 1 to 10, or a pharmaceutically acceptable salt thereof, for use in the treatment of nonalcoholic fatty liver disease (NAFLD).
21. A compound according to any one of Claims 1 to 10, or a pharmaceutically acceptable salt thereof, for use in the treatment of nonalcoholic steatohepatitis (NASH).
- 15 22. An intermediate compound of the following formula:
- His-Xaa2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-
Lys-Ala-Lys-Glu-Phe-Val-Glu-Trp-Leu-Leu-Xaa28-Gly-Gly-Pro-Ser-Ser-
Gly
- 20 wherein
- Xaa2 is Aib;
- Xaa28 is Glu or Ser; and
- the C-terminal amino acid is optionally amidated (SEQ ID NO: 9),
- or a pharmaceutically acceptable salt thereof.
- 25 23. The intermediate compound according to Claim 22, wherein Xaa28 is Glu.
- 24 The intermediate compound according to Claim 22, wherein Xaa28 is Ser.
25. A process for the manufacture of a compound of the following formula: